FGF21 analogs are being pursued as drug candidates for treating T2D as well as obesity and nonalcoholic steatohepatitis, and emerging human clinical trial data appears promising (14–16). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.